Perioperative medicine & outcomes
Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial
Authors' conclusion
This pilot study demonstrates the feasibility of, and provides guidance for, a future trial testing the efficacy of personalised perioperative ivabradine.
Study context
- Population
- Patients ≥75 yr or ≥45 yr with cardiovascular risk factors planned for intermediate- or high-risk noncardiac surgery
- Participants
- 78 patients
- Comparison
- Personalised HR-targeted perioperative ivabradine vs placebo
- Primary endpoint
- Appropriate dosage and blinding success rates
Methodological detailsfeasibility pilot, single-centre, placebo-controlled, double-blind, parallel group, Geneva University Hospitals, October 2020 to January 2022
- Feasibility pilot
- Single-centre
- Placebo-controlled
- Double-blind
- Parallel group
- Geneva University Hospitals, October 2020 to January 2022
Primary result
As reported in the abstract
Appropriate dosage rate (439 of 444 study drug administrations adequate)
99%
Blinding success rate
100%
Further findings
Recruitment rate
- Recruitment rate (patients week-1)
- 1.3
Administrations of Pill A (placebo in both groups for HR ≤70 beats min-1)
- Pill A administrations, 137
- 31%
High-sensitive cardiac troponin T elevation ≥14 ng L-1 between any two measurements
- Patients with troponin elevation, 9
- 11.5%
Safety
Events
| Outcome | Ivabradine | Placebo |
|---|---|---|
| Bradycardia episodes | 9 | 8 |
Original publication
Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial. Br J Anaesth. Published 2 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →